<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311100</url>
  </required_header>
  <id_info>
    <org_study_id>2016-53</org_study_id>
    <secondary_id>2017-A00778-45</secondary_id>
    <nct_id>NCT03311100</nct_id>
  </id_info>
  <brief_title>Immunological Profile of Solid Tumors Sample</brief_title>
  <official_title>Study of the Immunological Profile of Archival Formalin-fixed Paraffin-embedded Solid Tumors Sample</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has become clear in the recent year that the nature of the immune cells infiltrate within
      a tumor was essential in the control of the tumor growth. This so-called immune contexture
      does vary between cancer types and in response to treatments. In this context, this trial is
      a non-interventional, mono-centric in patients with solid tumors. Samples in
      paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or
      metastases) will be analysed. For each sample, clinically relevant data associated with
      treated cancer and needed for characterization of tumor microenvironment will be documented.

      This trial is, through accessing to well documented selected archival tumor materials, to
      validate selected biomarker for early phase trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">April 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunohistochemistry scores</measure>
    <time_frame>24 months</time_frame>
    <description>The immunohistochemistry scores is evaluated with the score of the percentage of stained cells.
Scale of the score of the percentage of stained cells, From 0 to 4, 0 : no stained cell (absence)
: &lt; 10 % stained cell (minimal)
: 10 to 50 % (mild)
: 51 to 79 % (moderate)
: = or &gt; 80 % (marked)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunohistochemistry scores</measure>
    <time_frame>24 months</time_frame>
    <description>The immunohistochemistry scores is evaluated with the score of the staining intensity.
Staining Intensity: from 0 to 3 0 : no staining (absence)
: low staining
: middle staining
: high staining</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1040</enrollment>
  <condition>Solid Cancer</condition>
  <arm_group>
    <arm_group_label>Lung cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Central Nervous System Cancers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and Neck and upper aero-digestive tract cancers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin cancers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcomas</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatocarcinoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry assay</intervention_name>
    <description>biomarkers expression</description>
    <arm_group_label>Lung cancer</arm_group_label>
    <arm_group_label>Central Nervous System Cancers</arm_group_label>
    <arm_group_label>Head and Neck and upper aero-digestive tract cancers</arm_group_label>
    <arm_group_label>Skin cancers</arm_group_label>
    <arm_group_label>Sarcomas</arm_group_label>
    <arm_group_label>Urothelial cancer</arm_group_label>
    <arm_group_label>Hepatocarcinoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples in formalin-fixed paraffin-embedded material block
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sample must have had a valid written informed consent for available archival tumor
             samples for scientific purposes.

          -  Sample from patients with histologically documented cancer in target population.

        Exclusion Criteria:

          -  Samples from subject unwilling to give their informed consent;

          -  Unusable sample or biologically deteriorated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ARNAUD Jean-Olivier, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BARLESI Fabrice, PU-PH</last_name>
    <phone>491385590</phone>
    <phone_ext>+33</phone_ext>
    <email>fabrice.barlesi@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BARLESI, PU-PH</last_name>
      <phone>491385590</phone>
      <phone_ext>+33</phone_ext>
      <email>fabrice.barlesi@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

